Biogen_Logo_Standard-rgb_R.jpg
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
23 févr. 2024 07h00 HE | Biogen Inc.
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development...
D Shelly PolTREG
PolTREG appoints Dan Shelly as Chief Business Development Officer
21 févr. 2024 01h00 HE | PolTREG S.A.
               Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
08 févr. 2024 16h02 HE | Athira Pharma, Inc.
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
fundamental pharma.png
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
07 févr. 2024 08h00 HE | Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic...
AB Science announces
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
26 janv. 2024 12h01 HE | AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN...
AB Science fait le p
AB Science fait le point sur la demande d’autorisation de mise sur le marché du masitinib dans la sclérose latérale amyotrophique auprès de l’Agence Européenne des Médicaments
26 janv. 2024 12h01 HE | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE D'AUTORISATION DE MISE SUR LE MARCHÉ DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE AUPRÈS DE L'AGENCE EUROPÉENNE DES...
Verge Logo.png
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635
09 janv. 2024 07h30 HE | Verge Genomics
VRG50635, a small molecule PIKfyve inhibitor, is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform Verge’s proof-of-concept study...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
08 janv. 2024 07h00 HE | Athira Pharma, Inc.
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Muscular Dystrophy Association Announces Acosta Group’s Historic $100 Million Fundraising Milestone
Muscular Dystrophy Association Announces Acosta Group’s Historic $100 Million Fundraising Milestone
21 déc. 2023 09h00 HE | Muscular Dystrophy Association
New York, Dec. 21, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today that long-term partner Acosta Group has reached a historic $100 million milestone in fundraising...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
12 déc. 2023 07h00 HE | Athira Pharma, Inc.
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...